Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
Rémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Haematologica (2018) Vol. 104, Iss. 1, pp. 138-146
Open Access | Times Cited: 46

Showing 26-50 of 46 citing articles:

Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis
Yannick Le Bris, Adeline Normand, Louise Bouard, et al.
eJHaem (2022) Vol. 3, Iss. 4, pp. 1165-1171
Open Access | Times Cited: 4
SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma
Dilan A. Patel, Brad S. Kahl
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 9, pp. 633-641
Open Access | Times Cited: 2
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Sylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Haematologica (2023)
Open Access | Times Cited: 2
Clinical management of mantle cell lymphoma in the elderly
Piotr Smolewski, Dominika Rydygier, Tadeusz Robak
Expert Opinion on Pharmacotherapy (2019) Vol. 20, Iss. 15, pp. 1893-1905
Closed Access | Times Cited: 5
Minimal residual disease (MRD) in mantle cell lymphoma
Marco Ladetto, Rita Tavarozzi, Christiane Pott
Annals of Lymphoma (2020) Vol. 4, pp. 4-4
Open Access | Times Cited: 5
Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma
Jia Ruan
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 5, pp. 871-885
Open Access | Times Cited: 5
Management of Older Adults with Mantle Cell Lymphoma
Jason T. Romancik, Jonathon B. Cohen
Drugs & Aging (2020) Vol. 37, Iss. 7, pp. 469-481
Closed Access | Times Cited: 4
Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
Xianhuo Wang, Yue Fei, Xia Liu, et al.
Aging (2021) Vol. 13, Iss. 17, pp. 21102-21121
Open Access | Times Cited: 4
The safety of available chemo-free treatments for mantle cell lymphoma
Anna Korycka, Dariusz Wołowiec, Tadeusz Robak
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 11, pp. 1377-1393
Closed Access | Times Cited: 3
Mantle Cell Lymphoma: Evolving Frontline Treatment Strategies
Inna Y. Gong, John Kuruvilla, Michael Crump
Canadian Hematology Today (2024)
Closed Access
Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis
Xue Wu, Hongyu Lu, Tao Pang, et al.
Leukemia Research (2021) Vol. 108, pp. 106605-106605
Closed Access | Times Cited: 3
Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma
André Goy
Expert Review of Hematology (2021) Vol. 14, Iss. 10, pp. 927-943
Closed Access | Times Cited: 2
Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?
Lindsay Hammons, Timothy S. Fenske
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1134-1134
Open Access | Times Cited: 1
Clinical Experience on Proteasome Inhibitors in Cancer
Noa Biran, Pooja Phull, André Goy
(2023), pp. 331-360
Closed Access
Study on autonomic neuropathy of the digestive system caused by bortezomib in the treatment of multiple myeloma
Weiwei Zhao, Juan Liu, Lianjie Wang, et al.
Hematology (2023) Vol. 28, Iss. 1
Open Access
The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma
Shuhua Yi, Yuting Yan, Yanshan Huang, et al.
Research Square (Research Square) (2023)
Open Access
Actualités dans les lymphomes à petites cellules non folliculaires
Clémentine Sarkozy, Gilles Salles
La Presse Médicale (2019) Vol. 48, Iss. 7-8, pp. 859-870
Open Access
GASTROINTESTINAL TRACT MULTIPLE LYMPHOMATOUS POLYPOSIS PRESENTED AS MANTLE CELL LYMPHOMA
Fatih Erkan Akay, Nuray Can, Mert Cezik, et al.
TURKISH MEDICAL STUDENT JOURNAL (2019) Vol. 6, Iss. 3, pp. 80-84
Open Access
Can We Use MRD Status to Personalize Therapy in Mantle Cell Lymphoma?
Brad S. Kahl
The Hematologist (2019) Vol. 16, Iss. 3
Open Access
An update on options of therapy for aggressive mantle cell lymphoma
Jia Ruan, Samuel Yamshon, Koen van Besien, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2020) Vol. 61, Iss. 9, pp. 2036-2049
Closed Access
Follicular and Mantle Cell Lymphomas: Technical and Interpretive Considerations; Karyotyping, FISH, Chromosomal Microarray, Sequencing, B Cell Clonality, Minimal Residual Disease
Eric Y. Loo
Molecular and translational medicine (2020), pp. 115-148
Closed Access
Previous Page - Page 2

Scroll to top